TORONTO -- Some recipients of the Moderna COVID-19 vaccine report having 鈥淐OVID arm,鈥 where a raised red lesion or rash occurs after inoculation, but experts say the reaction is harmless.
Presenting anywhere from five to 10 days after receiving the vaccine, the extremely rare 鈥淐OVID arm鈥 phenomenon may leave people with itchy and swollen skin around the injection site, or sometimes may present as red bumps or hives.
But experts say 鈥淐OVID arm鈥 is nothing but a harmless immune response that will fade within a week.
鈥淚t looks like a delayed allergic reaction,鈥 said clinical researcher and Toronto physician Dr. Iris Gorfinkel in a telephone interview with CTVNews.ca Saturday. 鈥淲hen people get redness from an injection site that is a predictable side effect of getting an injection, it's just what to expect.鈥
Gorfinkel said the 鈥淐OVID arm鈥 side effect isn鈥檛 鈥渦nique to COVID vaccines,鈥 in fact, it's not even 鈥渦nique to vaccines,鈥 citing similar reactions in people receiving tetanus, chicken pox and the MMR vaccine or simply having a mild topical allergic reaction.
鈥淎llergens don鈥檛 behave in necessarily predictable ways, but [COVID arm] is very unusual鈥t's happening in a very small group, it's also very mild, it's limited,鈥 Gorfinkel said, adding that it is 鈥渁bsolutely鈥 nothing to be concerned about.
鈥淭he risks of COVID-19 are far, far greater,鈥 she said.
Dr. Esther Freeman, director of global health dermatology at Boston鈥檚 Massachusetts General Hospital and the principal investigator in the global COVID-19 dermatological registry, told in January that 鈥淐OVID arm鈥 was a 鈥渒nown phenomenon鈥 and there is 鈥渘o indication鈥 the reaction is anything but a brief topical immune response from the body.
Freeman said that only 14 people had reported 鈥淐OVID arm鈥 in the global COVID-19 dermatological registry thus far.
鈥淐OVID arm鈥 symptoms were also reported in Moderna鈥檚 vaccine testing phases, as explained in an article in , with researchers reporting 244 participants experienced rash-like reactions after the first dose, and 68 participants noted similar symptoms after the second dose.
Gorfinkel warned that context is important when examining side effects for any vaccine, and said the reaction reported in the Moderna trials were out of 鈥渕ore than 30,000鈥 people, half of which received a placebo.
鈥淯nderstand that some 30,000 people received an injection of some kind, 15,000 of which received the active vaccine - so if you look at that as a fraction, it all of a sudden becomes not just small, but extremely small, so small that they may not have been able to even pick it up as a significant side effect,鈥 Gorfinkel explained.
鈥淭wo hundred and forty four people out of 15,000 is extremely small鈥hat's a fraction of a fraction who are experiencing it, and the benefits of vaccination far outweigh the disadvantages,鈥 she said.
鈥淐OVID arm鈥 has not been reported as often in recipients of the Pfizer vaccine, but Gorfinkel said that could be due to a myriad of reasons, and the answers will not be found until there is more data.
Dr. Isaac Bogoch, an infectious disease specialist at Toronto General Hospital, recently saw a case of 鈥淐OVID arm鈥 in one of his patients shortly after receiving the second dose of the Pfizer vaccine.
鈥淚t happened five days after their second dose. There was a little bit of tenderness and redness, but no constitutional symptoms, it was just restricted to the injection site on the arm,鈥 Bogoch told CTVNews.ca during a telephone interview on Saturday.
Bogoch said that his patient took some non-steroidal anti-inflammatory medication, similar to an Aspirin, and the patient鈥檚 symptoms went away a couple of days later.
He added that it is important to know these reactions are likely an immune response to the vaccine, but not every case is a cause for concern.
鈥淲hen you have mild reactions like this, many of them aren鈥檛 going to be reported, because they are mild and they鈥檙e self limited, so there鈥檚 going to be significant underreporting,鈥 said Bogoch.
Bogoch agrees with Gorfinkel that when the goal is to inoculate billions of people there will be more data available over time to explain why some individuals respond differently than others to the vaccination.
鈥淭hese are questions that need answering, but we don't have the massive data sets to do it yet,鈥 Gorfinkel said, adding that there hasn鈥檛 been 鈥渉ead-to-head [vaccine] trials yet,鈥 which would normally be the source of said data sets.
Gorfinkel said that anyone experiencing concerns or fears regarding side effects of COVID-19 vaccines, whether 鈥淐OVID arm鈥 or otherwise, should speak to their doctor.
